The study Peptide-ALPHA: a role of bladder regulatory peptides and alpha-blockers in combination therapy for LUTS

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Introduction. The pathogenesis of lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH) is quite complex and may be associated with overactive bladder (OAB). Alpha-1-blockers are not effective enough to resolve irritative LUTS caused by OAB. According to recent studies, regulatory polypeptides of the bovine urinary bladder (Vesusten) have shown their efficiency in patients with OAB.

Aim. To evaluate the efficiency and safety of combination therapy of LUTS caused by BPH with alpha-1-blockers and Vesusten in comparison with standard monotherapy with alpha-1-blockers.

Materials and methods. An open, prospective, randomized, single-center study was carried out. In the main group, patients received Vesusten intramuscularly 3 times a week (a total of 10 doses) and an alpha-1-adrenoblocker daily, while in the control group patients received alpha-blockers as monotherapy. Uroflowmetry and ultrasound parameters, IPSS and OAB-q questionnaires, as well as adverse events (AE) were assessed.

Results. A total of 100 patients were included in the study, 93 of whom completed the protocol. The baseline characteristics of the groups were comparable, all patients received selective alpha-adrenoblockers (silodosin or tamsulosin) before inclusion in the study. The IPSS change in the main group was -2.43, compared to -0.38 in the control group (p<0.001). OAB-q parameters also significantly improved in the main group (-2.89 vs. -0.12; p<0.001). There was a significant decrease in the frequency of urinations per 72 hours in the group of combination therapy (-3 vs. -0.17 in the monotherapy group; p<0.001). Also, the voided volume significantly increased in the main group by an average of 27.4 ml (p<0.001), and the postvoid residual volume decreased by an average of 10.7 ml. Qmax and Qave significantly improved in the main group (+1.7 ml/s and +1.5 ml/s vs. +0.1 ml/s and +0.1 ml/s in the control group, respectively; p<0.001). A total of 17 mild AEs associated with intramuscular administration of Vesusten were recorded.

Conclusions. The addition of Vesusten to alpha-blockers in patients with LUTS and OAB caused by BPH significantly reduced irritative symptoms according to questionnaires, uroflowmetry and postvoid residual volume. Only mild local AEs were observed that did not require discontinuation of therapy.

全文:

受限制的访问

作者简介

Leonid Spivak

FGAOU VO I.M. Sechenov First Moscow State Medical University

Email: leonid.spivak@gmail.com

Institute for Urology and Reproductive Health, Ph.D., M.D., professor

俄罗斯联邦, Moscow

Andrey Morozov

FGAOU VO I.M. Sechenov First Moscow State Medical University

编辑信件的主要联系方式.
Email: andrei.o.morozov@gmail.com

Institute for Urology and Reproductive Health, Ph.D., senior researcher

俄罗斯联邦, Moscow

Svetlana Bogatova

FGAOU VO I.M. Sechenov First Moscow State Medical University

Email: svetlanaidiatullina@mail.ru

Institute of Clinical Medicine named after N.V. Sklifosovskiy, student

俄罗斯联邦, Moscow

参考

  1. Benign prostatic hyperplasia: clinical guidelines/ Ministerstvo Zdravookhraneniya Rossiyskoy Federatsii, Obshcherossiyskaya obshchestvennaya organizatsiya «Rossiyskoye obshchestvo urologov». M., 2024. Russian (Доброкачественная гиперплазия предстательной железы: клинические рекомендации / Министерство здравоохранения Российской Федерации, Общероссийская общественная организация «Российское общество урологов». М., 2024).
  2. Radomski S.B. Update on medical therapy for male LUTS. Canadian Urological Association journal = Journal de l’Association des urologues du Canada. 2014;8(7-8 Suppl 5):S148–S150. https://doi.org/10.5489/cuaj.2310
  3. Burnett A.L., Walker D.R., Feng Q., Johnston K.M., Lozano-Ortega G., Nimke D., Hairston J.C. Undertreatment of overactive bladder among men with lower urinary tract symptoms in the United States: A retrospective observational study. Neurourology and urodynamics. 2020;39(5):1378–1386. https://doi.org/10.1002/nau.24348
  4. Huang T.X., Lo T.S., Tseng H.J., Lin Y.H., Liang C.C., Hsieh W.C. Correlation between overactive bladder and detrusor overactivity: a retrospective study. Int Urogynecol J. 2023;34(4):867–875.
  5. Peyronnet B., Mironska E., Chapple C., Cardozo L., Oelke M., Dmochowski R., Amarenco G., Gamé X., Kirby R., Van Der Aa F., Cornu J.N. A Comprehensive Review of Overactive Bladder Pathophysiology: On the Way to Tailored Treatment. Eur Urol. 2019;75(6):988–1000. https://doi.org/10.1016/j.eururo.2019.02.038
  6. Kuzmin I.V. Bioregulatory therapy of overactive bladder. Urologiia. 2024;2:92–99. Russian (Кузьмин И.В. Биорегулирующая терапия гиперактивного мочевого пузыря. Урология. 2024;2:92–99).
  7. Su S., Lin J., Liang L., Liu L., Chen Z., Gao Y. The efficacy and safety of mirabegron on overactive bladder induced by benign prostatic hyperplasia in men receiving tamsulosin therapy: A systematic review and meta-analysis. Medicine (Baltimore). 2020;99(4):e18802. doi: 10.1097/MD.0000000000018802. PMID: 31977871; PMCID: PMC7004736.
  8. Hao N., Tian Y., Liu W., Wazir R., Wang J., Liu L., Wang K., Li H. Antimuscarinics and α-blockers or α-blockers monotherapy on lower urinary tract symptoms – a meta-analysis. Urology. 2014;83(3):556–62. doi: 10.1016/j.urology.2013.10.034. Epub 2013 Dec 19. PMID: 24361007.
  9. Pushkar D.Yu., Kupriyanov Yu.A., Gamidov S.I. Evaluation of the safety and efficiency of the drug Vesusten in patients with overactive bladder. Urologiia. 2022;3:42–51 Doi: https: //dx.doi.org/10.18565/urology.2022.3.42-5. Russian (Пушкарь Д.Ю., Куприянов Ю.А., Гамидов С.И. Оценка безопасности и эффективности лекарственного препарата Везустен у пациентов с гиперактивным мочевым пузырем. Урология. 2022;3:42–51 Doi: https: //dx.doi.org/10.18565/urology.2022.3.42-5).
  10. Chalisova N.I., Melnikova Ya.V., Zalomaeva E.S. Determination of the biological activity of peptide bioregulators in organotypic tissue culture. Mezhdunarodnyy zhurnal prikladnykh i fundamental'nykh issledovaniy. 2017;6:274–277. Russian (Чалисова Н.И., Мельникова Я.В., Заломаева Е.С. Определение биологической активности пептидных биорегуляторов в органотипической культуре тканей. Международный журнал прикладных и фундаментальных исследований. 2017;6:274–277).
  11. Evdokimov V.V., Zakharikov S.V., Andreeva L.A. Effect of regulatory peptides on human sperm motility in vitro. Eksperimental'naya i klinicheskaya urologiia. 2016;2. Russian (Евдокимов В.В., Захариков С.В., Андреева Л.А. Влияние регуляторных пептидов на подвижность сперматозоидов человека in vitro. Экспериментальная и клиническая урология. 2016;2).
  12. Khochenkova Yu.A., Machkova Yu.S., Khochenkov D.A. Biological activity of a drug from testicular polypeptides in an in vitro model of oxidative stress. Eksperimental'naya i klinicheskaya urologiia. 2022;3. Russian (Хоченко- ва Ю.А., Мачкова Ю.С., Хоченков Д,А. Биологическая активность лекарственного препарата из полипептидов семенников в модели окислительного стресса in vitro. Экспериментальная и клиническая урология. 2022;3).
  13. Khochenkova Yu.A., Machkova Yu.S., Khochenkov D.A., Sidorova T.A., Safarova E.R., Bastrikova N.A., Korzhova K.V. Study of the mechanisms of action of the drug Fertiwell in vivo. Urologiia. 2023;1:60–70 doi: 10.18565/urology.2023.1.60-70. Russian (Хоченкова Ю.А., Мачкова Ю.С., Хоченков Д.А., Сидорова Т.А., Сафарова Э.Р., Бастрикова Н.А., Коржова К.В. Исследование механизмов действия препарата Фертивелл in vivo. Урология. 2023;1:60–70). doi: 10.18565/urology.2023.1.60-70
  14. Pushkar D.Yu., Kupriyanov Yu.A., Bernikov A.N. Evaluation of the safety and efficiency of a drug based on testicular regulatory polypeptides PPR-001. Urologiia. 2021;6:100–108. DOI: https://dx.doi.org/10.18565/urology.2021.6.100-108. Russian (Пушкарь Д.Ю., Куприянов Ю.А., Берников А.Н. Оценка безопасности и эффективности лекарственного препарата на основе регуляторных полипептидов семенников PPR-001. Урология. 2021;6:100–108. DOI: https://dx.doi.org/10.18565/urology.2021.6.100–108).
  15. Spivak L.G., Gamidov S.I., Al-Shukri S.Kh., Morozov A.O., Androsov A.A., Popova A.Yu., Kupriyanov Yu.A., Pushkar D.Yu. Assessment of long-term results of Fertiwell use: impact on the conception rate and pregnancy outcome. Urologiia. 2023;6:72–79. Doi: https: //dx.doi.org/10.18565/urology.2023.6.72-79. Russian (Спивак Л.Г., Гамидов С.И., Аль-Шукри С.Х., Морозов А.О., Андросов А.А., Попова А.Ю., Куприянов Ю.А., Пушкарь Д.Ю. Оценка отдаленных результатов применения препарата Фертивелл: влияние на вероятность зачатия и исход беременности. Урология. 2023;6:72–79. Doi: https: //dx.doi.org/10.18565/urology.2023.6.72-79).
  16. Kuzmenko A.V., Vinnik Yu.Yu., Kuzmenko V.V., Gyaurgiev T.A. The use of bioregulatory peptides in the treatment of men with benign prostatic hyperplasia and chronic prostatitis. Urologiia. 2021;3:70-74. DOI: https://dx.doi.org/10.18565/urology.2021.3.70-74 Кузьменко А.В., Винник Ю.Ю., Кузьменко В.В., Гяургиев Т.А. Применение биорегуляторных пеп- тидов в лечении мужчин с доброкачественной гиперплазией предстательной железы и хроническим простатитом. Урология. 2021;3:70-74 DOI: https://dx.doi.org/10.18565/urology.2021.3.70-74).
  17. Morozov A.O., Vovdenko S.V., Maltsagova P.Sh., Spivak L.G. Efficiency and safety of the drug Prostatex in patients with chronic prostatitis/chronic pelvic pain syndrome. Urologiia. 2023;2:41–47. DOI: https://dx.doi.org/10.18565/urology.2023.2.41-47. Russian (Морозов А.О., Вовденко С.В., Мальцагова П.Ш., Спивак Л.Г. Эффективность и безопасность препарата Простатекс у больных с хроническим простатитом/синдромом хронической тазовой боли. Урология. 2023;2:41–47. DOI: https://dx.doi.org/10.18565/urology.2023.2.41-47).

补充文件

附件文件
动作
1. JATS XML
下载
2. Fig. 1. Study design

下载 (143KB)
索引源数据
3. Fig. 2. Scheme of distribution of patients by study completion status

下载 (119KB)
索引源数据
4. Fig. 3. Dynamics of the sum of points on the IPSS scale

下载 (66KB)
索引源数据
5. Fig. 4. Dynamics of change in the average value of Qmax

下载 (67KB)
索引源数据
6. Fig. 5. Dynamics of change in the average value of Qave

下载 (65KB)
索引源数据
7. Fig. 6. Dynamics of residual urine volume according to ultrasound data of the bladder

下载 (65KB)
索引源数据

版权所有 © Bionika Media, 2025